Novolog Flexpen

Drug: NovoLog FlexPen
Company: Novo Nordisk
Total spend Q1, 2012: $26.4 million
Total spend Q1, 2011: $1.4 million
Watch the TV commercial here >>

While not quite in the blockbuster category, the NovoLog FlexPen still raked in about $755 million in U.S. sales for Novo Nordisk ($NVO), according to drugs.com. And in the first quarter, it generated about $227 million, a 9% increase. The FlexPen, which allows users to dial in doses, and use short needles for injection, is a big step up from taking insulin with a hypodermic needle. Still the holy grail is oral insulin. And Novo Nordisk says it's willing to bet $2 billion in R&D that it can score a megablockbuster success in the field. Until then, its patent for the FlexPen is protected for a couple more years and the company says making a biosimilar of its product is no easy deal, so it may be safe for some time.

Novolog Flexpen
Read more on

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.